Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel

Sponsor
ECOG-ACRIN Cancer Research Group
Study ID
NCT00900172
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — BIOLOGICAL
  • carboplatin — DRUG
  • paclitaxel — DRUG
  • gene expression analysis — GENETIC
  • polymerase chain reaction — GENETIC
  • polymorphism analysis — GENETIC
  • laboratory biomarker analysis — OTHER

Study Details

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at blood and tissue samples from patients with locally advanced, metastatic, or recurrent non-small cell lung cancer treated with bevacizumab, carboplatin, and paclitaxel.

Key Dates

First listed
May 12, 2009
Start date
Mar 15, 2008
Status verified
May 2017
Primary completion
Apr 15, 2009
Completion
Apr 15, 2009

Study Design

Enrollment
180 participants (actual)

Primary Outcome Measure

Correlation of results to response and toxicity [ Time Frame: 1 month ]

Related Studies